What does Ipsen do?
Ipsen is a global biopharmaceutical group focused on innovation and specialty care. The company develops and commercializes medicines in areas such as oncology, neurology, and endocrinology. Ipsen aims to improve patient outcomes by providing high-quality treatments and advancing scientific research.
- Sectors
- Wholesalers
- Signals
-
ProfitableProfitable € 4.17M
The company reported a positive net result in the latest financial year.
Strong equityStrong equity € 119.88MStrong equity provides a buffer against setbacks.
Low riskLow risk 89.2%Good solvency (> 30%) points to long-term financial stability.
Good liquidityGood liquidity 9.25A healthy current ratio (≥ 1.5): enough current assets to cover short-term debt.
Positive cashflowPositive cashflow € 4.21MPositive operating cash flow in the latest financial year.
Positive EBITDAPositive EBITDA € 3.45MPositive EBITDA: operating activities are profitable.
High turnoverHigh turnover € 71.32MSubstantial turnover in the latest financial year.
Healthy social debtHealthy social debt 20.3%Social debts stay manageable relative to personnel costs.
Financial ratios
|
|
2025
|
2024
|
2023
|
2022
|
|---|---|---|---|---|
|
€
71.32M
|
€
69.49M
|
€
66.18M
|
€
58.24M
|
|
|
€
3.45M
|
€
2.82M
|
€
2.20M
|
€
1.76M
|
|
|
€
4.17M
|
€
5.07M
|
€
3.77M
|
€
1.39M
|
|
|
€
119.88M
|
€
115.71M
|
€
110.65M
|
€
106.87M
|
|
|
89.23%
|
92.20%
|
87.45%
|
85.84%
|
|
|
€
14.48M
|
€
9.80M
|
€
15.88M
|
€
17.58M
|
|
|
€
252
|
€
350
|
|
|
|
|
38
|
42.50
|
42.10
|
38.90
|
Publications 89
All publications- Maatschappelijke Zetel - Ontslagen - Benoemingen 18/11/2025
- Maatschappelijke Zetel 12/02/2025
- Ontslagen - Benoemingen 03/10/2024
- Statuten (Vertaling, Cordinatie, Overige Wijzigingen, ) 20/03/2024
- Ontslagen - Benoemingen 03/11/2023
News
Show all- Ipsen Sa Estimates – Euronext:ipn TradingView 2 weeks ago
- Ipsen S.a. Upgrades Financial Guidance For The Full-Year 2026 www.marketscreener.com 2 weeks ago
- Ipsen Q3 2026 Slides: Sales Surge 26.7%, Guidance Raised On Rare Disease Investing.com Nigeria 2 weeks ago
- Capital Expenditures Of Ipsen Sa – Dus:i7G TradingView 2 weeks ago
- Ipsen Raises 2026 Guidance After Third Quarter Sales Beat Investing.com 2 weeks ago
Frequently asked questions
Answers to the most common questions about Ipsen, based on official government data and the filed annual accounts.
What is the VAT number of Ipsen?
The VAT number of Ipsen is BE0422.650.477.
What is the official website of Ipsen?
The official website of Ipsen is http://www.ipsen.com.
How many employees work at Ipsen?
In 2025, Ipsen employed 38.00 full-time equivalents (FTE).
When was Ipsen established?
Ipsen was founded in 09-04-1982.
What is the official address of Ipsen?
The official address of Ipsen is Guldensporenpark 87 Merelbeke-Melle 9820.
What is the legal form of Ipsen?
The juridical form of Ipsen is Public limited company (NV/SA).
What is the annual revenue of Ipsen?
The revenue of Ipsen for the 2025 financial year was €71,316,801.
What does Ipsen do?
Ipsen is a global biopharmaceutical group focused on innovation and specialty care. The company develops and commercializes medicines in areas such as oncology, neurology, and endocrinology. Ipsen aims to improve patient outcomes by providing high-quality treatments and advancing scientific research.
Is Ipsen a reliable company?
Ipsen is a registered Rechtspersoon with company number 0422.650.477 and can be verified through the official CBE database.
What is the credit limit of Ipsen?
The estimated credit limit of Ipsen is €10,000,000.
Is Ipsen still active?
Ipsen currently has the status "Normal situation" and is active.